This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BAKER, M. L. Articles by HUTSON, J. M. Search for Related Content PubMed PubMed Citation Articles by BAKER, M. L. Articles by HUTSON, J. M.

Serum Levels of Mullerian Inhibiting Substance in Boys from Birth to 18 Years, as Determined by Enzyme Immunoassay^*

Surgical Research Laboratory, Royal Children's Hospital Research Foundation Parkville, Victoria
The Department of Paediatrics, University of Melbourne Melbourne, Victoria, Australia

Address all correspondence and requests for reprints to: Sylvia A Metcalfe, PhD., Department of Surgery, Royal Children's Hospital, Flemington Road, Parkville, Victoria 3052, Australia.

An enzyme immunoassay was set up with the aim of determining the serum levels of Mullerian inhibiting substance (MIS) during childhood. A monoclonal antibody against purified bovine MIS was combined with a polyclonal antibody against recombinant human MIS to make a sandwich assay. This assay detected MIS in human serum within the following criteria. Ninety-eight boys, aged between birth and 18 yr, who had been admitted to the Royal Children's Hospital, were included. MIS levels were measured in samples taken for biochemical screening of unrelated disorders. MIS was detected in the serum up to 16 yr of age, but was low beyond 12 yr and undetectable at 18 yr. High MIS levels were found at 4–12 months, consistent with MIS having an important function at this time. Germ cells undergo an important transformation from gonocytes to spermatogonia at the same time as the MIS levels peak, suggesting a possible function for MIS.

^* This work was supported by the National Health and Medical Research Council of Australia.

Received March 14, 1989.

This article has been cited by other articles:

				R. Pieretti-Vanmarcke, P. K. Donahoe, P. Szotek, T. Manganaro, M. K. Lorenzen, J. Lorenzen, D. C. Connolly, E. F. Halpern, and D. T. MacLaughlin Recombinant Human Mullerian Inhibiting Substance Inhibits Long-term Growth of MIS Type II Receptor-Directed Transgenic Mouse Ovarian Cancers In vivo Clin. Cancer Res., March 1, 2006; 12(5): 1593 - 1598. [Abstract] [Full Text] [PDF]

				M. Misra, D. T. MacLaughlin, P. K. Donahoe, and M. M. Lee The Role of Mullerian Inhibiting Substance in the Evaluation of Phenotypic Female Patients with Mild Degrees of Virilization J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 787 - 792. [Abstract] [Full Text] [PDF]

				M. Misra, D. T. MacLaughlin, P. K. Donahoe, and M. M. Lee Measurement of Mullerian Inhibiting Substance Facilitates Management of Boys with Microphallus and Cryptorchidism J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3598 - 3602. [Abstract] [Full Text] [PDF]

				J. Teixeira, S. Maheswaran, and P. K. Donahoe Mullerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications Endocr. Rev., October 1, 2001; 22(5): 657 - 674. [Abstract] [Full Text] [PDF]

				P. T. Masiakos, D. T. MacLaughlin, S. Maheswaran, J. Teixeira, A. F. Fuller Jr., P. C. Shah, D. J. Kehas, M. K. Kenneally, D. M. Dombkowski, T. U. Ha, et al. Human Ovarian Cancer, Cell Lines, and Primary Ascites Cells Express the Human Mullerian Inhibiting Substance (MIS) Type II Receptor, Bind, and Are Responsive to MIS Clin. Cancer Res., November 1, 1999; 5(11): 3488 - 3499. [Abstract] [Full Text] [PDF]

				E. Rajpert-De Meyts, N. Jorgensen, N. Gram, J. Muller, R. L. Cate, and N. E. Skakkebak Expression of Anti-Mullerian Hormone during Normal and Pathological Gonadal Development: Association with Differentiation of Sertoli and Granulosa Cells J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3836 - 3844. [Abstract] [Full Text] [PDF]

				R. A. Rey, C. Belville, C. Nihoul-Fékété, L. Michel-Calemard, M. G. Forest, N. Lahlou, F. Jaubert, I. Mowszowicz, M. David, N. Saka, et al. Evaluation of Gonadal Function in 107 Intersex Patients by Means of Serum Antimullerian Hormone Measurement J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 627 - 631. [Abstract] [Full Text]

				M. M. Lee, P. K. Donahoe, B. L. Silverman, T. Hasegawa, Y. Hasegawa, M. L. Gustafson, Y. Chang, and D. T. MacLaughlin Measurements of Serum Mullerian Inhibiting Substance in the Evaluation of Children with Nonpalpable Gonads N. Engl. J. Med., May 22, 1997; 336(21): 1480 - 1486. [Abstract] [Full Text] [PDF]

				J. M. Hutson, S. Hasthorpe, and C. F. Heyns Anatomical and Functional Aspects of Testicular Descent and Cryptorchidism Endocr. Rev., April 1, 1997; 18(2): 259 - 280. [Abstract] [Full Text]